ThromboGenics Establishes Level 1 ADR Program for US Investors

Sep 30, 2013, 01:30 ET from ThromboGenics

LEUVEN, Belgium, September 30, 2013 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it has established a sponsored Level 1 American Depositary Receipt  (ADR) program. Trading of the ADRs commences today on the US over the counter (OTC) market under the ticker TBGNY.

ThromboGenics' ADRs are US dollar negotiable certificates with each ADR representing half of one ordinary share of the Company. J.P. Morgan has been appointed as the depositary bank for the ThromboGenics' ADR program.

ADR effective date:  September 30, 2013

Symbol: TBGNY

     Traded: OTC

     Ratio 2 ADRs: 1 Ordinary Share

     CUSIP: 886003 10 2

     Local ISIN: BE0003846632

     Country of incorporation: Belgium

     Industry: Biopharmaceutical

     Depositary: JPMorgan Chase Bank, N.A.

     Custodian: BNP Paribas, Belgium

For questions related to the ThromboGenics ADR Program, please contact J.P. Morgan shareholder services:

J.P. Morgan Depositary Bank

1 Chase Manhattan Plaza, Floor 58

New York, NY 10005

In the U.S.: (866) JPM-ADRS  

Outside the U.S.: (+1 866  576-2377)

Or visit J.P. Morgan Depositary Receipts Services at

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.  

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA® in the UK, Germany, Denmark, Norway, Finland and Sweden.  

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction.  No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

SOURCE ThromboGenics